5-(pentafluorobenzoylamino)fluorescein di-β-D-glucopyranoside | 209540-62-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-(pentafluorobenzoylamino)fluorescein di-β-D-glucopyranoside
• 英文别名: PFB-FDGlu；2,3,4,5,6-pentafluoro-N-[3-oxo-3',6'-bis[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]spiro[2-benzofuran-1,9'-xanthene]-5-yl]benzamide
• CAS: 209540-62-5
• 化学式: C₃₉H₃₂F₅NO₁₆
• 分子量: 865.672
• InChiKey: YYMJMZGTQFITLS-WXKYVOLFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  61
• 可旋转键数：
  8
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  263
• 氢给体数：
  9
• 氢受体数：
  21

文献信息

• NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM
  申请人：Boyd Robert

  公开号：US20110092541A1

  公开（公告）日：2011-04-21

  The present invention provides novel compounds as well as compositions and methods using the same for preventing and/or treating degenerative disorders of the central nervous system. In particular, the present invention provides methods for preventing and/or treating Parkinson's disease.

  本发明提供了新颖的化合物，以及使用这些化合物预防和/或治疗中枢神经系统退行性疾病的组合物和方法。具体来说，本发明提供了预防和/或治疗帕金森病的方法。
• METHODS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM
  申请人：Boyd Robert

  公开号：US20100261753A1

  公开（公告）日：2010-10-14

  The present invention provides methods for preventing and/or treating degenerative disorders of the central nervous system using 5-(fluoromethyl)piperidine-3,4-diol, 5-(chloromethyl)piperidine-3,4-diol, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, or any combination of two or more thereof. In particular, the present invention provides methods for preventing and/or treating Parkinson's disease.

  本发明提供了使用5-(氟甲基)哌啶-3,4-二醇、5-(氯甲基)哌啶-3,4-二醇、或其药学上可接受的盐、溶剂或前药，或以上两种或以上的任意组合，预防和/或治疗中枢神经系统退行性疾病的方法。特别地，本发明提供了预防和/或治疗帕金森病的方法。
• Novel Compositions for Preventing and/or Treating Degenerative Disorders of the Central Nervous System
  申请人：AMICUS THERAPEUTICS, INC.

  公开号：US20140080871A1

  公开（公告）日：2014-03-20

  The present invention provides novel compounds as well as compositions and methods using the same for preventing and/or treating degenerative disorders of the central nervous system. In particular, the present invention provides methods for preventing and/or treating Parkinson's disease.

  本发明提供了一种新型化合物，以及使用该化合物的组合物和方法，用于预防和/或治疗中枢神经系统的退行性疾病。特别是，本发明提供了预防和/或治疗帕金森病的方法。
• Novel Compositions for Preventing and/or Treating Lysosomal Storage Disorders
  申请人：Amicus Therapeutics, Inc.

  公开号：US20140086896A1

  公开（公告）日：2014-03-27

  The present invention provides novel compositions as well as methods for preventing and/or treating lysosomal storage disorders. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease.

  本发明提供了新型组成物以及预防和/或治疗溶酶体贮存疾病的方法。特别是，本发明提供了预防和/或治疗高氏病的方法。
• Genz 112638 for treating Gaucher or Fabry disease in combination therapy
  申请人：Genzyme Corporation

  公开号：EP2796457A1

  公开（公告）日：2014-10-29

  The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described.

  由以下结构式代表的化合物的半酒石酸盐： (式Ⅰ酒石酸半酒石酸盐），可用于制药。式 (I) 半酒石酸盐的特定单晶形式具有各种特性和物理测量值。此外，还讨论了生产结晶型式（I）酒石酸半乳糖酯的方法，以及用其抑制葡萄糖酰胺合成酶或降低受试者体内糖磷脂浓度以治疗多种疾病的方法。还介绍了药物组合物。